337 related articles for article (PubMed ID: 10896986)
1. [Contribution of intravenous immunoglobulins to the treatment of myasthenia].
Gajdos P
Ann Med Interne (Paris); 2000 May; 151 Suppl 1():1S30-4. PubMed ID: 10896986
[TBL] [Abstract][Full Text] [Related]
2. [Therapeutic strategy in myasthenia gravis].
Tranchant C
Rev Neurol (Paris); 2009 Feb; 165(2):149-54. PubMed ID: 19233080
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic options in autoimmune myasthenia gravis.
García-Carrasco M; Escárcega RO; Fuentes-Alexandro S; Riebeling C; Cervera R
Autoimmun Rev; 2007 Jun; 6(6):373-8. PubMed ID: 17537383
[TBL] [Abstract][Full Text] [Related]
4. Management of myasthenia gravis.
Schwendimann RN; Burton E; Minagar A
Am J Ther; 2005; 12(3):262-8. PubMed ID: 15891271
[TBL] [Abstract][Full Text] [Related]
5. Intravenous immune globulin in myasthenia gravis.
Gajdos P
Clin Exp Immunol; 1994 Jul; 97 Suppl 1(Suppl 1):49-51. PubMed ID: 8033435
[TBL] [Abstract][Full Text] [Related]
6. Myasthenia gravis: management of myasthenic crisis and perioperative care.
Juel VC
Semin Neurol; 2004 Mar; 24(1):75-81. PubMed ID: 15229794
[TBL] [Abstract][Full Text] [Related]
7. Clinical correlates with anti-MuSK antibodies in generalized seronegative myasthenia gravis.
Evoli A; Tonali PA; Padua L; Monaco ML; Scuderi F; Batocchi AP; Marino M; Bartoccioni E
Brain; 2003 Oct; 126(Pt 10):2304-11. PubMed ID: 12821509
[TBL] [Abstract][Full Text] [Related]
8. The immune system, Part 2: Myasthenia gravis.
Stephens A
Nurs Times; 1997 Nov 12-18; 93(46):56-9. PubMed ID: 9418490
[No Abstract] [Full Text] [Related]
9. Myasthenia gravis.
Silvestri NJ; Wolfe GI
Semin Neurol; 2012 Jul; 32(3):215-26. PubMed ID: 23117946
[TBL] [Abstract][Full Text] [Related]
10. Therapy in myasthenia gravis and Lambert-Eaton myasthenic syndrome.
Newsom-Davis J
Semin Neurol; 2003 Jun; 23(2):191-8. PubMed ID: 12894384
[TBL] [Abstract][Full Text] [Related]
11. Myasthenic crisis: guidelines for prevention and treatment.
Jani-Acsadi A; Lisak RP
J Neurol Sci; 2007 Oct; 261(1-2):127-33. PubMed ID: 17544450
[TBL] [Abstract][Full Text] [Related]
12. Plasma exchange for treatment of myasthenia gravis: pathophysiologic basis and clinical experience.
Qureshi AI; Suri MF
Ther Apher; 2000 Aug; 4(4):280-6. PubMed ID: 10975474
[TBL] [Abstract][Full Text] [Related]
13. [Intensive care in myasthenic and cholinergic crises].
Popova LM; Piradov MA
Anesteziol Reanimatol; 1996; (2):13-5. PubMed ID: 8754165
[TBL] [Abstract][Full Text] [Related]
14. [Ocular myasthenia: a diagnostic and management challenge--a review].
Langmann A; Lindner S; Koch M; Diez J
Klin Monbl Augenheilkd; 2004 Feb; 221(2):77-86. PubMed ID: 14986204
[TBL] [Abstract][Full Text] [Related]
15. Myasthenia gravis crisis.
Bershad EM; Feen ES; Suarez JI
South Med J; 2008 Jan; 101(1):63-9. PubMed ID: 18176295
[TBL] [Abstract][Full Text] [Related]
16. Myasthenia gravis: effect of immunoactive therapies.
Fornádi L; Horváth R; Bárdosi Z; Szobor A
Acta Med Hung; 1994; 50(1-2):83-92. PubMed ID: 7638045
[TBL] [Abstract][Full Text] [Related]
17. [Ocular myasthenia: diagnosis and treatment].
Stojkovic T; Béhin A
Rev Neurol (Paris); 2010 Dec; 166(12):987-97. PubMed ID: 21075410
[TBL] [Abstract][Full Text] [Related]
18. [Myasthenia gravis. Indications, aims and methods of intensive therapy].
Braschi A; Scherini A; Carbonera D; Mapelli A; Bellinzona G; Bobbio Pallavicini F; Dionigi R; Gasperi A
Minerva Anestesiol; 1979 Nov; 45(11):871-81. PubMed ID: 548812
[TBL] [Abstract][Full Text] [Related]
19. Autoimmune aspects of myasthenia gravis.
Lisak RP; Levinson AI; Zweiman B
Concepts Immunopathol; 1985; 2():65-101. PubMed ID: 3916415
[No Abstract] [Full Text] [Related]
20. Therapeutic strategies for myasthenia gravis.
Keys PA; Blume RP
DICP; 1991 Oct; 25(10):1101-8. PubMed ID: 1803801
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
